Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Virology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IPPK drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IPPK Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW. Suitable for enzymatic assays and biophysical screening. |
View IPPK Products |
| Gene Delivery | IPPK Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for target validation and cellular IP6 quantification assays. |
View IPPK Products |
| Benchmark Ab | Anti-IPPK Recombinant Antibody Recombinant positive control for Western Blot, ELISA, and intracellular localization studies. |
View IPPK Products |
| Validator | IPPK siRNA Set For knockdown verification in target validation and phenotypic assays. |
View IPPK Products |
| Related Target A | IP6K1 Inositol hexakisphosphate kinase 1. Synthesizes 5-IP7 from IP6; critical node in the inositol pyrophosphate signaling cascade. |
View IP6K1 Products |
| Related Target B | PPIP5K1 Diphosphoinositol pentakisphosphate kinase 1. Works in tandem with IP6K to regulate cellular energy homeostasis and signaling. |
View PPIP5K1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic Activity & ATP Consumption | High purity (>95%) recombinant IPPK protein ensures low background ATPase activity in ADP-Glo assays. |
| Kinase Subfamily Selectivity | Homolog panel proteins (IP6K1, PPIP5K1) strictly verified by mass spectrometry for off-target counter-screening. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and positive control expression plasmids included. |
| False Positives in Small Molecule Screens | Validated siRNA sets included for cellular target knockdown to confirm on-target phenotype. |
Live IPPK R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IPPK therapeutics is intensifying, with major players shifting focus from traditional oncology targets to host-directed antiviral therapies and immunometabolism. IPPK (Inositol-pentakisphosphate 2-kinase) is the sole enzyme responsible for converting IP5 to IP6 in mammalian cells. Because IP6 is a mandatory host cofactor for HIV-1 genomic RNA packaging and immature particle assembly, targeting host IPPK represents a high-barrier-to-resistance strategy for antiviral drug discovery. As first-generation therapies reach the clinic, the next wave of R&D is targeting selective small-molecule inhibitors that disrupt IP6 biosynthesis without causing systemic toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule | Gilead Sciences, Academic Consortia | HIV-1 Infection, Solid Tumors | Selectivity Assay (Need High-Purity IPPK vs IP6K1/PPIP5K1 panels) |
| siRNA / RNAi | Alnylam, Arrowhead | Chronic Viral Infections, Oncology | Knockdown Verification (Need Sequence-Verified siRNA and Lentivirus) |
| PROTAC / Degraders | Arvinas, Biotech Startups | Refractory Cancers | Target Ubiquitination (Need Recombinant IPPK with precise tags for ternary complex assays) |